NON-ALCOHOLIC FATTY LIVER DISEASE OUTCOMES FUNNEL
https://doi.org/10.17749/2070-4909.2015.8.3.014-019
Abstract
Introduction. Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as an important and common public health problem that can lead to cirrhosis and hepatic failure (hepatocellular carcinoma – HCC). It may be the most prevalent liver disease. However knowledge of the epidemiology is limited. Most data came from studies conducted in Northern America, Western Europe, Japan and China. A first disease registry in NAFLD (DIREG_L_01903) was performed in 2007 in Russia. This study showed high prevalence of NAFLD within the GP-s patient flow (27%). These findings encourage to conduct a larger sample size study to evaluate the real prevalence of NAFLD in the Russian population and if this prevalence of NAFLD patients has changed in the last 7 years.
About the Author
D. V. Blinov
The Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, Moscow
Russian Federation
Russian Federation
MD, PhD, Pirogov Russian National Research Medical University (RNRMU). Address: Ostrovitianov str. 1, Moscow, 117997, Russia. E-mail: blinov2010@gmail.com.
References
1. Babak O.Ya., Kolesnikova E.V., Dubrov K.Yu. Ukrainskii terapevticheskii zhurnal. 2011; 1: 5.
2. Babak O.Ya., Kolesnikova E.V., Shut' I.V., Kurinnaya E.G., Sytnik K.A. Gastroenterologiya. 2013; 47 (1): 54-59.
3. Bazin I.S., Omel'yanovskii V.V., Avksent'eva M.V. Meditsinskie tekhnologii. Otsenka i vybor. 2010; 2: 22-27.
4. Blinov D.V., Zimovina U.V., Ushakova T.I. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2015; 1: 31-38.
5. Vikulov G.Kh. Farmateka. 2011; 5: 21-26.
6. Got'e S.V., Moisyuk Ya.G., Khomyakov S.M. Vestnik transplantologii i iskusstvennykh organov. 2014; 2: 5-23.
7. Got'e S.V., Moisyuk Ya.G., Khomyakov S.M. Vestnik transplantologii i iskusstvennykh organov. 2015; 2: 7-22.
8. Drapkina O.M., Ivashkin V.T. RZhGGK. 2014; 4: 32-38.
9. Drapkina O.M., Smirin V.I., Ivashkin V.T. Lechashchii vrach. 2010; 5 (5): 57-61.
10. Ignat'eva V.I., Avksent'eva M.V. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2014; 3: 3-11 / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology.
11. Kucheryavyi Yu.A., Stukova N.Yu., Akhtaeva M.L. Klinicheskie perspektivy gastroenterologii, gepatologii. 2012; 5: 3-11.
12. Lipatova L.V. Epilepsiya i paroksizmal'nye sostoyaniya / Epilepsy and paroxysmal conditions. 2010; 3: 20-27.
13. Makarov I.O., Borovkova E.I., Kazakov R.D. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction. 2012; 4: 18-21.
14. Makarov I.O., Pavlov Ch.S., Shemanaeva T.V., Voevodin S.M., Muravei A.Yu. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction. 2013; 1: 22-25.
15. Proceedings of the meeting the Minister of Health of the Russian Federation V. Skvortsova with members of the Federation Council Committee on Social Policy. 03/24/2015. Remedium [Materialy vstrechi ministra zdravookhraneniya RF V. Skvortsovoi s chlenami komiteta Soveta Federatsii RF po sotsial'noi politike. 24.03.2015. Remedium (In Russian)]. http://remedium.ru/news/detail.php?ID=65259. Accessed 26.06.2015.
16. Odinak M.M., Bazilevich S.N., Dyskin D.E., Prokudin M.Yu. Epilepsiya i paroksizmal'nye sostoyaniya / Epilepsy and paroxysmal conditions. 2010; 3: 45-50.
17. Pavlov Ch.S., Glushenkov D.V., Bulichenko M.A., Vorob'ev A.V., Nikonov E.L., Ivashkin V.T. RMJ. 2010; 28: 1742-1748
18. Pal'gova L.K. Consilium medicum. Gastroenterologiya. 2014; 1: 18-23.
19. Pogrebnichenko I.V. Effective use of multiorgan donor liver transplantation. PhD. Diss. [Effektivnoe ispol'zovanie pecheni mul'tiorgannogo donora dlya transplantatsii. Diss. ...kand. med. Nauk (in Russian)]. Moscow. 2014; 143 s.
20. Polivanov V.A. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2009; 1: 7-11.
21. Sas E.I., Blinov D.V., Zimovina U.V. Klinicheskie perspektivy gastroenterologii, gepatologii. 2015; 1: 9-17.
22. Cherkashina E.A., Petrenko L.V., Evstigneeva A.Yu. Ul'yanovskii mediko-biologicheskii zhurnal. 2014; 1: 35-47.
23. Yakovleva T.V. Speech at the 7th All-Russian Congress of Transplantation. [Vystuplenie na 7-m Vserossiiskom S'ezde transplantologov (in Russian)]. 28-30 May 2014.
24. Byrne C.D., Targher G. NAFLD: a multisystem disease. J Hepatology. 2015; 62: 47-64.
25. Chagas A.L., Kikuchi L.O.O., Oliveira C.P.M.S. et al. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? Braz. J. Med. Biol. Res. 2009; 42 (10): 958-962.
26. Charlton M.R., Burns J.M., Pedersen R.A., Watt K.D., Heimbach J.K., Dierkhising R.A. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011; 141: 1249-1253.
27. de Marco R., Locatelli F., Zoppini G., Verlato G., Bonora E., Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care. 1999; 22: 756-761.
28. Drapkina O., Evsyutina Y., Ivashkin V. Prevalence of non-alcoholic fatty liver disease in the Russian Federation: the open, multicenter, prospective study, DIREG 1. American Journal of Clinical Medicine Research. 2015; 3 (2): 31-36.
29. Ekstedt M., Franzen L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G. Lonf-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44: 865-873.
30. Ekstedt M., Hagstrom H., Nasr P., Fredrickson M., Stal P., Kechagias S. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015.
31. Eurotransplant Annyal Report 2014. Eurotransplant International Foundation. 2014; 160 p.
32. Gomaa A.I., Khan S.A., Toledano M.B. et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. Wld J. Gastroenterol. 2008; 14 (27): 4300-4308.
33. Mishra A., Younossi Z.M. Epidemiology and natural history of nonalcoholic fatty liver disease. J Clin Exp Hepatol. 2012; 2: 135-144;
34. Pacana T., Fuchs M. The cardiovascular link to nonalcoholic fatty liver disease. Clin Liver Dis. 2012; 16: 599-613.
35. Shariff M.I.F., Cox I.J., Gomaa A.I. et al. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Exp. Rev. Gastroenterol. 2009; 3 (4): 353-367.
36. Takuma Y., Nouso K. Nonalcoholic steatohepatitis associated hepatocellular carcinoma: our case series and literature review. Wld J. Gastroenterol. 2010; 16 (12): 1436-1441.
37. Tapper E., Sengupta N., Hunink M., Afdhal N.H., Lai M. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography. Am J Gastroenterol. 2015; 110: 1298-1304.
38. Waly Raphael S., Yangde Z., Yuxiang C. Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol. 2012; 1-12.
39. Welsh J.A., Karpen S., Vos M.B. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 19881994 to 2007-2010. J Pediatrics. 2013; 162 (3): 496-500.
40. Yang J.D., Roberts L.R. Epidemiology and management of hepatocellular carcinoma. Infect. Dis. Clin. North. Am. 2010; 24 (4): 899-919.
41. Younossi Z.M., Henry L. Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease. PharmacoEconomics. 2015; DOI 10.1007/s40273-015-0316-5.
42. YounossiZ.M.,OtgonsurenM.,HenryL.,VenkatesanC.,MishraA., Erario M., Hunt S. Association of Non-alcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States from 2004-2009. Hepatology. 2015 Aug 14. DOI: 10.1002/hep.28123.
43. Zhang E., Wartelle-Bladou C., Lepanto L., Laclaine J., Cloutier G., Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol. 2015; DOI 10.1007/s00330-015-3731-2.
Review
For citations:
Blinov D.V. NON-ALCOHOLIC FATTY LIVER DISEASE OUTCOMES FUNNEL. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2015;8(3):14-19. (In Russ.) https://doi.org/10.17749/2070-4909.2015.8.3.014-019
Views: 1048
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 